Pediatrix Medical Group, INC

Pediatrix Medical Group announced robust second quarter 2026 financial results, exceeding prior year performance with increased net revenue and improved adjusted EBITDA.

Pediatrix Medical Group, Inc. reports on the departure of its Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, Mary Ann E. Moore, and the appointment of David Haddock as the new General Counsel and Secretary.

Pediatrix Medical Group provided a second quarter update, confirming a stable payor mix and reaffirming its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million.

Pediatrix Medical Group shareholders approved an amended incentive compensation plan, increasing available shares and ratifying auditor appointment at the 2026 Annual Meeting.

Pediatrix Medical Group reported strong first-quarter results, exceeding expectations with net revenue of $476 million and Adjusted EBITDA of $58 million, driven by improved reimbursement and strategic acquisitions.

Pediatrix Medical Group announced fourth-quarter and full-year 2025 results, reporting Adjusted EPS of $0.50 for Q4 and providing a preliminary 2026 Adjusted EBITDA outlook.

Pediatrix Medical Group announced a 4.0% increase in net revenue for the second quarter of 2026, driven by acquisitions and same-unit revenue growth, alongside a rise in net income.

Pediatrix Medical Group reports a significant increase in net income and operating income for the first quarter of 2026, driven by acquisitions and improved same-unit revenue.

Pediatrix Medical Group reports a significant turnaround in Q3 and year-to-date 2025, driven by strategic divestitures, improved operational efficiency, and robust cash flow.

Pediatrix Medical Group reports a significant return to profitability in Q2 2025, driven by strategic divestitures and strong same-unit revenue growth.

Pediatrix Medical Group's Q1 2025 net income increased significantly to $20.7 million, driven by same-unit revenue growth and the impact of practice dispositions.

Pediatrix Medical Group's Q3 2024 results reflect a strategic shift towards hospital-based and maternal-fetal medicine, impacting financials with significant impairment charges and restructuring costs.

Pediatrix Medical Group, Inc. reported a significant turnaround in 2025, achieving $165.4 million in net income and $275.6 million in Adjusted EBITDA, driven by strategic portfolio optimization and improved same-unit revenue.

Pediatrix Medical Group's 2024 10-K filing reveals a strategic shift towards hospital-based and maternal-fetal medicine, alongside challenges including a goodwill impairment and revenue cycle management transformation.

Pediatrix Medical Group's 10-K filing details its national physician network, business strategy, and financial performance for the year ended December 31, 2023.

David Haddock, EVP, GC & Corp Sec of Pediatrix Medical Group, Inc., was granted restricted shares and performance share units.

EVP and General Counsel Mary Ann E. Moore transferred 18,407 shares of Pediatrix Medical Group common stock to a family trust.

Kasandra H. Rossi, EVP, CFO and Treasurer of Pediatrix Medical Group, Inc., reported transactions involving restricted stock grants and tax withholdings.

Pediatrix Medical Group, Inc. Chief Executive Officer Mark S. Ordan reports transactions involving restricted stock, including grants and tax withholdings.

Don Gregory Neeb, EVP Chief Invest & Strategy at Pediatrix Medical Group, Inc., reported transactions involving restricted stock and tax withholdings.

Pediatrix Medical Group, Inc. executive Mary Ann E. Moore reported a transaction involving common stock, including shares withheld for tax payments.

Pediatrix Medical Group, Inc. announced its 2026 Annual Shareholders Meeting to vote on director elections, auditor ratification, executive compensation, and a key incentive compensation plan amendment.

Pediatrix Medical Group will hold its annual shareholder meeting on May 8, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory vote.

Pediatrix Medical Group will hold its 2025 Annual Shareholders Meeting virtually on May 8, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.

Pediatrix Medical Group will hold its annual shareholder meeting on May 9, 2024, featuring proposals to elect directors, ratify the appointment of PricewaterhouseCoopers LLP, and conduct an advisory vote on executive compensation.

Pediatrix Medical Group has released its proxy statement for the 2024 Annual Shareholders Meeting, detailing proposals for director elections, auditor ratification, and executive compensation.

BlackRock, Inc. has filed an amendment to its Schedule 13G, revealing a beneficial ownership of 14.6% in Pediatrix Medical Group, Inc.'s common stock.

AllianceBernstein L.P. has filed an Amendment No. 6 to Schedule 13G, disclosing a 2.2% beneficial ownership stake in Pediatrix Medical Group Inc. as of May 31, 2025.

AllianceBernstein L.P. has filed an amended Schedule 13G, reporting an 8.0% passive ownership stake in Pediatrix Medical Group Inc. as of March 31, 2025.

Rubric Capital Management LP and David Rosen have reported a 3.67% beneficial ownership stake in Pediatrix Medical Group, Inc. as of December 31, 2024, held for investment purposes.